Under the leadership of Anton Krucky, Tissue Genesis has emerged as a respected and forward-looking leader in the regenerative medicine industry. Mr. Krucky is a former IBM executive and served as General Manager of Operations for IBM Pacific. He has extensive global management and executive experience in product development, marketing, and sales.
Dr. Marc Penn directs the medical research of Tissue Genesis. In addition, Dr. Penn is CEO of Black Beret Life Sciences, providing oversight and management of the life sciences investments of the Bosarge Family Office and the executive teams of the portfolio companies in the areas of regenerative medicine, anti-aging and immune therapies.
Rajesh (R.K.) Khosla serves on the Board of Managers of Tissue Genesis and is also Chief Operating Officer of Black Beret Life Sciences, LLC. R.K. was most recently CEO at Laguna Pharmaceuticals (formerly ChanRx Corp.), a company developing drug treatments for atrial fibrillation/atrial flutter. He was also CEO-in-Residence at BioEnterprise Corp. helping companies accelerate their growth to benefit the Northeastern Ohio economy.
An internationally recognized expert in vascular biology and tissue engineering, Dr. Stuart Williams is a leader in endothelial cell isolation technology. He is credited with developing and patenting the technique for isolating human stem cells from fat tissue.
Dr. Paul Kosnik is responsible for business development and managing interactions with the clinical trial sites and medical experts. He also serves as the Tissue Genesis Principal Investigator for the Critical Limb Ischemia trial funded by the federal government.
Tom Cannon is the co-inventor of the Tissue Genesis Icellator Cell Isolation System®, Bio-Optimization System, and BIOS cell culture system. He is responsible for key technology assets and relationships with technology providers, leading researchers, and end users of Tissue Genesis technology.
Cristine Kosnik is the Director of Quality Assurance at Tissue Genesis responsible for the management of design controls, documentation, corrective and preventive action, customer feedback, production, and validation.
Dr. Rolf Wolters is responsible for Product Development and Product Management at Tissue Genesis. He is also the Principal Investigator for the Department of Defense phase II SBIR for advanced cell isolation technology (NIMBUS Project).
Dr. Mike Winegar has over thirty years of experience in global medical device regulatory affairs, regulatory compliance, quality assurance, and clinical research, with an emphasis on neurovascular, cardiovascular, and peripheral vascular technologies. Dr. Winegar guides the Tissue Genesis regulatory affairs activities.
Dr. Jenny Lee is responsible for product characterization through flow cytometry and biological functional assays as well as enzyme development and evaluations. Dr. Lee received her Ph.D. (Summa Cum Laude) from the University of Heidelberg with an emphasis in molecular and cell biology.